# A Study to Assess the Efficacy and Safety of ASKP1240 in de Novo Kidney Transplant Recipients

> **NCT01780844** · PHASE2 · COMPLETED · sponsor: **Astellas Pharma Global Development, Inc.** · enrollment: 149 (actual)

## Conditions studied

- Kidney Transplantation

## Interventions

- **DRUG:** ASKP1240
- **DRUG:** Tacrolimus
- **DRUG:** Mycophenolate Mofetil (MMF)
- **DRUG:** Basiliximab
- **DRUG:** Methylprednisone
- **DRUG:** Prednisone

## Key facts

- **NCT ID:** NCT01780844
- **Lead sponsor:** Astellas Pharma Global Development, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-03-05
- **Primary completion:** 2014-06-30
- **Final completion:** 2017-01-27
- **Target enrollment:** 149 (ACTUAL)
- **Last updated:** 2025-11-21

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01780844

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01780844, "A Study to Assess the Efficacy and Safety of ASKP1240 in de Novo Kidney Transplant Recipients". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT01780844. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*